NCT05412290View on ClinicalTrials.gov

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 22, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

August 31, 2028

Conditions
B Cell LymphomaAggressive LymphomaDiffuse Large B Cell LymphomaHigh-grade B-cell LymphomaTransformed LymphomaFollicular Lymphoma Grade 3
Interventions
DRUG

Mosunetuzumab

"Mosunetuzumab is administered intravenously in a step-up dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following."

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER